Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069713 | 0.89 | ALDH1A1 (0.49) | MAOBUSP2GAAALDH1A1MAPT | |
| SCHEMBL10069270 | 0.88 | MAOB (0.50) | MAOBUSP2ALDH1A1TRPM8MAPT | |
| SCHEMBL6011774 | 0.88 | ALDH1A1 (0.53) | MAOBGAAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL27637229 | 0.88 | GAA (0.45) | MAOBUSP2GAAALDH1A1MAPT | |
| SCHEMBL6011987 | 0.87 | MAOB (0.51) | MAOBUSP2ALDH1A1MAPTHPGD | |
| SCHEMBL14261845 | 0.86 | TDP1 (0.51) | MAOBUSP2GAAALDH1A1MAPT | |
| SCHEMBL14261857 | 0.86 | MAOB (0.50) | MAOBUSP2ALDH1A1MAPTHPGD | |
| SCHEMBL14261822 | 0.83 | TSHR (0.48) | MAOBUSP2ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL14261840 | 0.82 | GPR119 (0.48) | MAOBALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL6011718 | 0.82 | MAOB (0.53) | MAOBALDH1A1TRPM8MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1785415-B1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1785415-A1 | PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070898-A1 | Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof | TRPV1, TRPA1, CACNA1D | MAOB 3198/4885USP2 4045/4885GAA 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.